Utah Medical Products Inc. Common Stock (UTMD)

FairStock Score: 44/100 — MIXED

Key Financials

Strengths

• Generates $11 million in annual free cash flow (5.2% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Conservative balance sheet with debt-to-equity of just 0.00, providing financial flexibility
• Altman Z-Score of 41.9 confirms minimal bankruptcy risk and strong solvency

Concerns

• Revenue declining at 1.2% year-over-year signals potential demand weakness or market share loss

AI Analysis

Utah Medical Products Inc. Common Stock is a micro-cap healthcare company valued at $215 million. The business generates $39 million in annual revenue with a 7.1% net margin and $11 million in free cash flow. From a quality standpoint, Utah shows solid Piotroski F-Score of 7/9 and Altman Z-Score of 41.9 confirms fortress-level solvency. On valuation, the stock is reasonably priced at 19.5x earnings, with trades above its Graham Number with a negative 24% margin. Growth dynamics show revenue growing at -1.2% and profit growth of -11.6%. The 1.8% dividend yield adds an income component for patient holders. Our composite FairStock Score of 44/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $11 million in annual free cash flow (5.2% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer